CONNECT WITH US
AI & Deeptech

AI & Deeptech

Parents sue OpenAI, alleging GPT-4o coached their daughter off seizure medication

TechCrunch – AI logo

Published on

Add as a preferred source on Google
Parents sue OpenAI, alleging GPT-4o coached their daughter off seizure medication

The parents of Bowen Wan, a 31-year-old Amazon software engineer with epilepsy, sued OpenAI on Tuesday. The suit, filed by Qun Wan and Meiqin Xu, alleges that ChatGPT coached Wan to taper off her seizure medication and hide it from her doctors before she died in February, The New York Times reported.

Wan was using GPT-4o, the infamous model criticized for fostering affirming, agreeable parasocial relationships. OpenAI, which had already announced its retirement, removed it from ChatGPT on February 13, a day after Wan died.

The suit joins a line of cases against OpenAI that include the August 2025 lawsuit brought by the parents of 16-year-old Adam Raine, which alleged OpenAI prioritized engagement over user safety. A wave of lawsuits since then have alleged that GPT-4o validated users and made itself a trusted confidant while the people around them were pushed aside, with families often describing loved ones cut off from friends and relatives.

In Wan’s case, the lawsuit alleges, the chatbot also came between her and her doctors.

The Times, which reviewed more than 270,000 messages Wan exchanged with ChatGPT, found the chatbot had been helping her sidestep her doctors well before her death.

The pattern allegedly started before she began tapering. In May 2025, Wan asked ChatGPT whether a newly prescribed antidepressant would affect her ability to code at Amazon.

ChatGPT helped her ask Dr. Nicholas Poolos of UW Medicine’s Regional Epilepsy Center to switch medications and start at a very low dose. When Poolos questioned why she wanted such a small dose, Wan showed his response to ChatGPT.


Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.